Recombinant Proteins for the Treatment of SARS-COV2 Disease

JP2024544264APending Publication Date: 2024-11-28UNICHEM LAB LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024535288
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-16
Filing Date
2022-12-14
Publication Date
2024-11-28

AI Technical Summary

Benefits of technology

【0047】 表のリスト Table 1(表2).配列番号2の組換えスクレロチウム·ロルフシーレクチンのスパイクS1タンパク質とACE2タンパク質との結合の阻害に対する効果 Table 2(表3).配列番号2の組換えスクレロチウム·ロルフシーレクチンの48時間後の免疫細胞(THP-1)の生存率に対する効果 Table 3(表4).配列番号2の組換えスクレロチウム·ロルフシーレクチンの48時間後の肺(A549)細胞の生存率に対する効果 Table 4(表5):注射用の配列番号2の組換えスクレロチウム·ロルフシーレクチンの免疫細胞(THP-1)において変異体SARS-COV-2-スパイクS1(E484K)タンパク質によって誘導されたサイトカインのレベルに対する阻害効果 Table 5(表6):注射用の配列番号2の組換えスクレロチウム·ロルフシーレクチンの肺細胞(A549)において変異体SARS-COV-2-スパイクS1(N501Y)タンパク質によって誘導されたサイトカインのレベルに対する阻害効果 Table 6(表8):注射用の配列番号2の組換えスクレロチウム·ロルフシーレクチンのカテプシンLの阻害に対する効果 Table 7(表10):注射用の配列番号2の組換えスクレロチウム·ロルフシーレクチンの3CLの阻害に対する効果 Table 8(表12):注射用の配列番号2の組換えスクレロチウム·ロルフシーレクチンのDPP4の阻害に対する効果 Table 9(表13):配列番号2の組換えスクレロチウム·ロルフシーレクチンのスパイクS1タンパク質(SARS-COV-2)によって誘導された膀胱細胞(T24)における炎症マーカーの発現に対する阻害効果 Table 10(表14):配列番号2の組換えスクレロチウム·ロルフシーレクチンのスパイクS1タンパク質(SARS-COV-2)によって誘導された心臓細胞(H9C2)における炎症マーカーの発現に対する阻害効果 Table 11(表15):配列番号2の組換えスクレロチウム·ロルフシーレクチンのスパイクS1タンパク質(SARS-COV-2)によって誘導された結腸細胞(HT-29)における炎症マーカーの発現に対する阻害効果 Table 12(表16):配列番号2の組換えスクレロチウム·ロルフシーレクチンのスパイクS1タンパク質(SARS-COV-2)によって誘導された血管内皮細胞(EA.hy926)における炎症マーカーの発現に対する阻害効果 Table 13(表17):配列番号2の組換えスクレロチウム·ロルフシーレクチンのスパイクS1タンパク質(SARS-COV-2)によって誘導された腎臓細胞(HEK-293)における炎症マーカーの発現に対する阻害効果 Table 14(表18):配列番号2の組換えスクレロチウム·ロルフシーレクチンのスパイクS1タンパク質(SARS-COV-2)によって誘導された骨細胞(MG-63)における炎症マーカーの発現に対する阻害効果 Table 15(表19):配列番号2の組換えスクレロチウム·ロルフシーレクチンのスパイクS1タンパク質(SARS-COV-2)によって誘導された肝細胞(HepG2)における炎症マーカーの発現に対する阻害効果 Table 16(表20):配列番号2の組換えスクレロチウム·ロルフシーレクチンのスパイクS1タンパク質(SARS-COV-2)によって誘導された膵臓細胞(PANC-1)における炎症マーカーの発現に対する阻害効果

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544264000001
    Figure 2024544264000001
  • Figure 2024544264000002
    Figure 2024544264000002
  • Figure 2024544264000003
    Figure 2024544264000003
Patent Text Reader

Abstract

The present invention relates to a protein for the treatment of infectious diseases caused by coronaviruses. In particular, the present invention relates to a recombinant S. rolfsii lectin for use in treating, slowing the progression, and curing SARS-COV2 disease in a subject in need thereof. A pharmaceutical composition comprising said recombinant S. rolfsii lectin is also described. The recombinant S. rolfsii lectin protein may comprise an amino acid sequence having at least 70% homology to SEQ ID NO:1.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the use of lectin proteins for the prevention, treatment and cure of SARS-Cov2 disease. [Background technology]

[0002] Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the respiratory disease that led to the deadly coronavirus disease 2019 (COVID-19) pandemic. In late 2019, the SARS-CoV-2 outbreak was first reported in Wuhan, China, and has since led to a truly global crisis (Huang et al., 2020). Coronaviruses (CoVs) are large, enveloped, nonsegmented, positive-stranded RNA viruses. CoVs generally cause mild enteric and respiratory diseases in animals and humans (Glass et al., 2004). Most human CoVs, such as hCoV-229E, OC43, NL63, and HKU1, usually cause only mild respiratory disease (Fouchier et al., 2004). SARS-CoV-2 causes an acute, potentially fatal pneumonia with clinical symptoms similar to those reported for SARS-CoV and MERS-CoV-2 (Fouchier et al., 2004). In contrast to SARS-CoV, patients infected with SARS-CoV-2 rarely exhibit prominent upper respiratory tract signs and symptoms. Based on recent literature, most severe SARS-CoV-2 cases deteriorated within 14–21 days after disease onset. Interestingly, these risk factors are similar to those reported in association with MERS-CoV-related mortality (diabetes, hypertension, obesity), although MERS-CoV respiratory disease occurred in younger individuals (Assiri et al., 2013; World Health Organization, 2013).

[0003] The coronavirus genome consists of about 30000 nucleotides. This genome encodes four structural proteins, nucleocapsid (N) protein, membrane (M) protein, spike (S) protein, and envelope (E) protein, as well as several nonstructural proteins (nsp) (Figure 1). The capsid is a protein shell, and inside the capsid is the nucleocapsid or N-protein, which binds to the single-stranded positive-stranded RNA of the virus, allowing the virus to hijack the human cell and turn the human cell into a virus factory. To enter the host cell, coronaviruses first bind to cell surface receptors for virus binding, then enter the endosome, and finally fuse the viral membrane with the lysosomal membrane. The viral surface anchor spike (S) protein binds to the angiotensin-converting enzyme 2 (ACE2) receptor found on the surface of many human cells, including human cells in the lungs, allowing viral entry. The coronavirus S protein undergoes proteolytic cleavage by host proteases (i.e., trypsin and furin) at two sites located at the interface between the S1 and S2 subunits (S1 / S2 sites). At a later stage, cleavage of the S2 domain (S2' site) occurs to release the fusion peptide. This event triggers the activation of the membrane fusion machinery. These clinical and epidemiological observations provide direction regarding the mechanism of disease and elucidate that the virus enters its host cells via the ACE2 receptor.

[0004] Viruses mutate, and SARS-CoV-2 is no exception. Throughout the recent global crisis, SARS-CoV-2 has mutated at a rate of approximately 1-2 mutations per month. Various mutations of this virus have been reported around the world. Mutations in the spike protein may affect the infectivity of the virus. Mutations in the spike protein have been reported to play a role in the antigenicity of the virus, and these mutations have different effects on different cell lines (Qianqian Li et al., 2020). Viral mutations may prolong the pandemic and increase the risk of further mutations of the virus emerging, which may weaken the efficacy of existing vaccines in individuals over time, and the emergence of new variants poses serious concerns for mutations that are likely to evade vaccines.

[0005] The range of pharmacological therapies to combat coronavirus disease 2019 (COVID-19) is rapidly expanding and evolving. The range of treatment options currently available for Covid19 includes convalescent plasma, corticosteroid medications (dexamethasone), azithromycin, hydroxychloroquine and chloroquinone, ivermectin, Kaletra, monoclonal antibodies (MABs), bamlanivimab (LY-CoV555), and bamlanivimab and etesevimab; combinations of casirivimab and imdevimab, tocilizumab, IL-6 inhibitors, kinase inhibitors such as acalabrutinib (Olumient), ruxolitinib (Jakavi), and tofacitinib (Xeljanz); repurposed medications oseltamivir, favipiravir, and vaccines such as Covishield, Covaxin, the Moderna vaccine, Sputnik, Sinovac, and Janssen COVID-19. Although many treatment options are available, the cost of treatment and the rapid mutation of COVID19 are obstacles to current treatment options for COVID19.

[0006] The presence of glycoproteins in the viral envelope opens up a great opportunity for the application of lectins to address several pressing issues involved in this pandemic (LuisClaudio et al., 2021). The SARS-CoV-2 envelope displays glycoproteins such as the spike (S-protein) and membrane (M-protein) proteins (Ahmed, SF, Quadeer, AA et al., 2020; Shajahan, A., Supekar, NT et al., 2020) (Supplementary Figure 1A). These structural proteins, especially the S-protein, have been shown to play a central role in viral pathogenesis and are important targets for neutralizing antibodies, vaccines, and drug design (Ahmed, SF, Quadeer, AA et al., 2020; Bagdonaite, I., and Wandall, HH 2018). One study evaluated the in vitro antiviral activity of 33 plant lectins against coronaviruses (SARS-CoV and feline infectious peritonitis virus). Mannose-binding agglutinin showed the best anti-SARS-CoV effect. Other plant lectins have been shown to exert inhibitory effects against other coronaviruses. Examples include the following mannose-binding lectins: concanavalin A (Con A), Hippeastrum hybrid agglutinin (HHA), and Galanthus nivalis agglutinin (GNA or GNL) (Greig, AS and Bouillant, AM 1977; Hsieh, LE, Lin, CN et al. 2010; Nguyen, TD, Bottreau, E. et al. 1987; van der Meer, FJ, de Haan, CA et al. 2007a). One of these studies highlighted the importance of glycosylation in the susceptibility of two coronaviruses (mouse hepatitis virus and feline infectious peritonitis virus) to GNA, UDA, and HHA. In this case, inhibition of host mannosidases led to enhanced antiviral activity of mannose- and GlcNAc-binding lectins (van der Meer, FJ, de Haan, CA et al. 2007b).

[0007] Non-plant derived agglutinins have also been pointed out as promising agents against coronaviruses, e.g., the mannose-binding lectins cyanovirin-N (from the cyanobacterium Nostoc ellipsosporum) and griffithsin (from the red seaweed Griffithsia spp.) (O'Keefe, BR, Giomarelli, B. et al., 2010; van der Meer, FJ, de Haan, CA et al., 2007a). However, only griffithsin (GRFT) has been evaluated against SARS-CoV and MERS-CoV. This protein binds with high affinity to multiple sites on the glycoproteins of SARS-CoV and MERS-CoV and inhibits viral entry (Millet, JK, Seron, K. et al., 2016; O'Keefe, BR, Giomarelli, B. et al., 2010). Moreover, this lectin also reduced the mortality and severity of a lethal lung infection induced by SARS-CoV in mice. This effect is associated with a reduction in proinflammatory cytokines in infected lung tissue (O'Keefe, BR, Giomarelli, B. et al., 2010). Some plant lectins such as mannose-binding lectin, phytohemagglutinin succ-Con A, lentil lectin, and lectin isolated from Lablab purpureus (FRIL) for the treatment or prevention of SARS-Cov2 have also been investigated in patent applications WO2021 / 222965, CN113262294, CN113274484, WO2021 / 226294. Despite the potential antiviral activity of the aforementioned lectins, several limitations must be considered regarding their therapeutic utility. One practical problem is that these macromolecules are rapidly degraded, requiring multiple administrations to maintain therapeutic levels.

[0008] Sclerotium rolfsii lectin (SRL) is a lectin isolated from the sclerotium of the soil-borne plant pathogen S. rolfsii. SRL has specificity for the Thomsen-Friedrich (TF) antigen, Tn antigen, and its extended core structure. The TF antigen is a disaccharide (Galβ1→3GalNAc-α-Ser / Thr) that is overexpressed on the cell surface of various human cancer cells. The Tn antigen is a monosaccharide (GalNAc-α-Ser / Thr). TF or T antigen is an intermediate structure in the biosynthesis of complex O-linked oligosaccharides. Its formation is carried out by the addition of galactose (Gal) from UDP-Gal to the precursor structure GalNAc (Tn antigen). Applicant's previous application WO2010 / 095143 discloses recombinant lectin variants Rec-2 and Rec-3, which are obtained by substituting three or five amino acids, respectively, from the native SRL sequence. The crystal structures of these variants have been reported (Peppa et al., Molecules. 2015 Jun. 12;20(6):10848-65). WO2014 / 203261 discloses recombinant lectin variants obtained by substituting 12 amino acids from the native SRL sequence. Anti-inflammatory properties of recombinant Sclerotium rolfsii lectin have also been disclosed in Applicant's previous application WO2020 / 074984.

[0009] Today, there are few biologics approved for the treatment of SARS-CoV2 disease. They are very expensive, produced in low quantities, and difficult to obtain due to high demand. Therefore, there is an unmet need to provide an option for the treatment of SARS-Cov2 that is highly specific for its action, inexpensive, and effectively fulfills the market need. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] WO2021 / 222965 [Patent Document 2] CN113262294 [Patent Document 3] CN113274484 [Patent Document 4] WO2021 / 226294 [Patent Document 5] WO2010 / 095143 [Patent Document 6] WO2014 / 203261 [Patent Document 7] WO2020 / 074984 [Non-patent literature]

[0011] [Non-Patent Document 1] Peppa et al., Molecules. 2015 June 12;20(6):10848~65 [Non-Patent Document 2] Altschul et al., Nucleic Acids Res. 1997 September 1;25(17):3389~402 Summary of the Invention [Problem to be solved by the invention]

[0012] Therefore, it is an object of the present invention to provide recombinant Sclerotium rolfsii lectin for use in the treatment or prevention of SARS-CoV2 disease in a subject in need thereof.

[0013] Therefore, it is an object of the present invention to provide a therapeutic method using recombinant Sclerotium rolfsii lectin for the treatment or prevention of SARS-CoV2 disease in a subject in need thereof.

[0014] Therefore, it is an object of the present invention to provide a composition comprising recombinant Sclerotium rolfsii lectin for the treatment or prevention of SARS-CoV2 disease to a subject in need thereof. [Means for solving the problem]

[0015] In a first aspect of the present invention there is provided a recombinant Sclerotium rolfsii lectin for use in the treatment or prevention of an infectious disease caused by a Coronaviridae in a subject in need thereof.

[0016] In a second aspect of the present invention, there is provided a pharmaceutical composition comprising recombinant Sclerotium rolfsi lectin and a pharma- ceutically acceptable diluent or excipient, optionally comprising a further therapeutic agent.

[0017] In a third aspect of the present invention, there is provided a method for treating or preventing an infectious disease caused by a Coronaviridae in a subject, the method comprising administering to the subject a recombinant Sclerotium rolfsii lectin or a pharmaceutical composition of the second aspect of the present invention.

[0018] In a fourth aspect of the present invention, there is provided a use of recombinant S. rolfsii lectin or a pharmaceutical composition comprising recombinant S. rolfsii lectin for the treatment or prevention of an infectious disease caused by a Coronaviridae in a subject.

[0019] In yet another aspect of the present invention, there is provided a recombinant Sclerotium rolfsii lectin protein for use in the treatment or prevention of an infectious disease caused by a virus selected from SARS-CoV2, SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, and variants thereof.

[0020] In yet another aspect of the present invention, there is provided a recombinant Sclerotium rolfsii lectin protein for use in the treatment or prevention of an infectious disease caused by a virus selected from SARS-CoV2 and its variants.

[0021] The lectin may comprise an amino acid sequence at least 60% identical to SEQ ID NO: 1. In some embodiments, the lectin comprises an amino acid sequence at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1. In some embodiments, the lectin comprises the amino acid sequence of SEQ ID NO: 1. The lectin protein may be recombinant.

[0022] In yet another aspect of the present invention, there is provided a recombinant Sclerotium rolfshii lectin protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4.

[0023] In yet another aspect of the present invention, there is provided a recombinant S. rolfsii lectin protein for use in the treatment or prevention of SARS-Cov2 and its mutants or variants, which is capable of inhibiting viral entry by blocking SARS-CoV2 spike S1 protein and ACE2 and inhibiting or modulating mutant spike S1 protein (from SARS-COV-2) induced cytokine storm in lung and immune cells. The recombinant S. rolfsii lectin protein interferes with SARS-CoV-2 entry by AT1R downregulation in cells and significantly inhibits proteases associated with Covid pathogenesis, and the recombinant S. rolfsii protein also significantly inhibits cytokines such as IL6 and IL8 in lung cells (A549) and immune cells (THP-1) compared to controls.

[0024] Another aspect of the present invention is to provide a recombinant Sclerotium rolfsii lectin protein for the treatment of SARS-CoV2.

[0025] Yet another aspect of the present invention is to provide a method for the treatment of SARS-CoV2 and its variants using recombinant Sclerotium rolfsii lectin protein.

[0026] Yet another aspect of the present invention is to provide a method for curing or reducing the effects of SARS-CoV2 in a subject suffering from the disease. The present invention also relates to a method for treating SARS-CoV2, which comprises administering a lectin protein. The lectin protein can be administered in an amount ranging from about 0.001 mg to 50 mg / kg of the subject's body weight. The lectin protein can be administered per se or in a pharma-ceutically acceptable form.

[0027] The lectin protein can be administered to a subject by injection of a solution or suspension intravenously, intramuscularly, intraperitoneally, subcutaneously, intradermally, by depot injection, intrathecally, transdermally, sublingually, or orally, topically, or by inhalation methods.

[0028] As used herein, the term "lectin" refers to a carbohydrate-binding protein.

[0029] As used herein, the term "protein" refers to a polymer of amino acid residues.

[0030] The term "amino acid" as used herein refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that have similar functions as naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code and include proteinogenic amino acids. Naturally occurring amino acids also include amino acids that are post-translationally modified in cells. Synthetic amino acids include non-standard amino acids such as selenocysteine ​​and pyrrolysine. Typically, synthetic amino acids are not proteinogenic amino acids.

[0031] It is understood that amino acids can be grouped according to different biochemical properties. Examples include polar amino acids, non-polar amino acids, acidic amino acids, and basic amino acids. In one embodiment, the amino acid used for the amino acid modification is at least one selected from the group consisting of, but not limited to, polar, non-polar, acidic, basic, selenocysteine, pyrrolysine, and non-standard.

[0032] The term "homology" or "homologous" as used herein refers to two or more references that share at least partial identity over a given range or portion. A region, range, or domain of homology or identity refers to a portion of two or more references that share homology or are the same. Thus, two sequences share identity over one or more sequence ranges if they are identical. Substantial homology refers to a structurally or functionally conserved molecule, and thus the molecule has or is predicted to have at least a partial structure or function (e.g., biological function or activity) of the reference molecule, or a related / corresponding range or portion of the reference molecule that shares homology.

[0033] In one embodiment, the percentage "homology" of two sequences is determined using the BLASTP algorithm with default parameters. (Altschul et al., Nucleic Acids Res. 1997 Sep. 1;25(17):3389-402). In particular, the BLAST algorithm can be accessed on the Internet using the URL: https: / / blast.ncbi.nlm.nih.gov / Blast.cgi. In an alternative embodiment, for global sequence alignment, the percentage homology of two sequences is determined using the EMBOSS Needle algorithm with default parameters. In particular, the EMBOSS Needle algorithm can be accessed on the Internet using the URL: https: / / www.ebi.ac.uk / Tools / psa / emboss_needle / .

[0034] Unless otherwise indicated, the term "homology" is used interchangeably with the term "sequence identity" herein.

[0035] The term "coronavirus" refers to large, enveloped, single-stranded RNA viruses. They are the largest known RNA viruses, with genomes ranging from 25 to 32 kb and viral particle diameters of 118 to 140 nm.

[0036] The term spike protein or "S" protein, used interchangeably, is a large type I transmembrane protein ranging from 1,160 up to 1,400 amino acids. Moreover, this protein is highly glycosylated as it contains 21-35 N-glycosylation sites. The spike protein assembles into trimers on the surface of the virus particle, forming a unique "crown" or crown-like appearance. The ectodomain of all CoV spike proteins shares the same organization with two domains: the N-terminal domain designated S1, involved in receptor binding, and the C-terminal S2 domain, involved in fusion. The diversity of CoVs is reflected in the variable spike protein (S protein), which has evolved into different forms for interaction with receptors and response to various environmental factors for virus-cell membrane fusion. The spike protein or "S" protein can be obtained from SARS-CoV2 or its variants.

[0037] The term "ACE2" refers to a protein on the surface of many cell types. It is an enzyme that cleaves the larger protein angiotensinogen to produce smaller proteins that then control functions within the cell. ACE2 is present in the epithelium of the nose, mouth, and lungs. In the lungs, ACE2 is highly abundant on type 2 pneumocytes, an important cell type that resides in chambers within the lungs called alveoli, where oxygen is absorbed and consumed carbon dioxide is released. ACE2 helps regulate much of the activity of a protein called angiotensin II (ANGII), which increases blood pressure and inflammation, and increases damage to blood vessel linings and various types of tissue injury. ACE2 converts ANGII into other molecules that counteract the effects of ANGII.

[0038] As used herein, the terms "administer", "administering" or "administration" refer to implanting, absorbing, ingesting, injecting, inhaling or otherwise introducing a compound of the present invention or a pharmaceutical composition thereof.

[0039] An "effective amount" of a compound or any active ingredient as described herein means an amount sufficient to induce a desired biological response, i.e., to treat a condition. As will be understood by those skilled in the art, the effective amount of a compound may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the condition to be treated, the mode of administration, and the age and health of the subject. An effective amount includes therapeutic and prophylactic treatments.

[0040] The compositions described herein can be mixed with a pharma- ceutically acceptable carrier or excipient to form a pharmaceutical composition for use in inhibiting coronavirus and / or treating infection caused by the SARS-CoV2 virus.

[0041] The terms "inhibiting," "inhibit," "inhibit," "inhibitor," and the like refer to the ability of an anti-coronavirus agent to reduce, slow, stop, or prevent the activity of a particular biological process (e.g., coronavirus replication) in a cell relative to a control. In some cases, the anti-coronavirus agent can inhibit the level of viral replication by at least 20% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%).

[0042] The terms "treating" or "treatment" refer to administering one or more anti-coronavirus agents (e.g., compositions described herein) to a subject (e.g., a human patient) with SARS-Cov2 infection, symptoms thereof, or predisposition to infection, for the purpose of providing a therapeutic effect, e.g., curing, alleviating, altering, affecting, ameliorating, or preventing the infection, symptoms thereof, or predisposition to infection. Such subjects may be identified by medical personnel based on the results of any appropriate diagnostic method.

[0043] The term "infectious disease" refers to the invasion of body tissues of an organism by disease-causing pathogens, their proliferation, and the host tissue's response to the infectious agents and the toxins they produce. Infectious diseases, also known as communicable diseases or contagious diseases, are illnesses caused by infection. Infections are caused by infectious agents including bacteria, fungi, viruses, prions, parasites, and arthropods.

[0044] The terms "SARS-Cov2" or "Covid-19" or "Covid" or "Coronavirus disease", used interchangeably, refer to the infectious disease caused by the virus SARS-CoV2, or variants thereof.

[0045] The term "mutant" is defined as an organism or new genetic characteristic that arises or results from a mutation, generally a change in the DNA sequence of the genome or chromosomes of an organism. This is a characteristic not naturally observed in a specimen. The term mutant is also used for viruses whose genomes are in the nuclear genome and have changes in the nucleotide sequence. [Sequence table free text]

[0046] SEQ ID NO:1 represents the native S. rolfsi lectin amino acid sequence. TYKITVRVYQTNPNAFFHPVEKTVWKYANGGTWTITDDQHVLTMGGSGTSGTLRFHADNGESFTATFGVHNYKRWCDIVTNLAADETGMVINQQYYSQKNREEARERQLSNYEVKNAKGRNFEIVYTEAEGNDLHANLIIG SEQ ID NO:2 represents a variant of the S. rolfsi lectin amino acid sequence (reported as Rec-2 in WO2010 / 095143). TYKITVRVYQTNPDAFFHPVEKTVWKYANGGTWTITDDQHVLTMGGSGTSGTLRFHADNGESFTATFGVHNYKRWCDIVTNLAADETGMVINQQYYSQKNREEARERQLSNYQVKNAKGRNFQIVYTEAEGNDLHANLIIG SEQ ID NO:3 represents a variant of the S. rolfsi lectin amino acid sequence (reported as Rec-3 in WO2010 / 095143). VYKITVRVYQTNPDAFFHPVEKTVWKYANGGTWSITDDQHVLTMGGSGTSGTLRFHADNGESFTATFGVHNYKRWCDIVTNLAADETGMVINQQYYSQKNREEARERQLSNYQVKNAKGRNFQIVYTEAEGNDLHANLIIG SEQ ID NO:4 represents a variant of the S. rolfsi lectin amino acid sequence (reported in WO2014 / 203261). VYKITVRVYQTNPDAFFHPVEKTVWKYADGGTWSITDDQHVLTMGGSGTSGTLRFHADNGESFTATFGVHDYKRWCDIVTDLAADETGMVINQEYYSEKDREEARERQNSNYEVKDAKGRNFEIVYTEAEGNDLHADLIIG

[0047] List of Tables Table 1. Effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 on inhibiting the binding of spike S1 protein to ACE2 protein. Table 2. Effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 on the viability of immune cells (THP-1) after 48 hours. Table 3. Effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 on the viability of lung (A549) cells after 48 hours. Table 4: Inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO: 2 for injection on the levels of cytokines induced by mutant SARS-COV-2-spike S1 (E484K) protein in immune cells (THP-1) Table 5: Inhibitory effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 for injection on the levels of cytokines induced by mutant SARS-COV-2-spike S1 (N501Y) protein in lung cells (A549) Table 6: Effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 for injection on inhibition of cathepsin L Table 7: Effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 for injection on the inhibition of 3CL Table 8: Effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 for injection on the inhibition of DPP4 Table 9: Inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO: 2 on the expression of inflammatory markers in bladder cells (T24) induced by spike S1 protein (SARS-COV-2) Table 10: Inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO: 2 on the expression of inflammatory markers in cardiac cells (H9C2) induced by spike S1 protein (SARS-COV-2) Table 11: Inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO: 2 on the expression of inflammatory markers in colon cells (HT-29) induced by spike S1 protein (SARS-COV-2) Table 12: Inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO: 2 on the expression of inflammatory markers in vascular endothelial cells (EA.hy926) induced by spike S1 protein (SARS-COV-2) Table 13: Inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO: 2 on the expression of inflammatory markers in kidney cells (HEK-293) induced by spike S1 protein (SARS-COV-2). Table 14: Inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO: 2 on the expression of inflammatory markers in bone cells (MG-63) induced by spike S1 protein (SARS-COV-2) Table 15: Inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO: 2 on the expression of inflammatory markers in hepatocytes (HepG2) induced by spike S1 protein (SARS-COV-2) Table 16: Inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO: 2 on the expression of inflammatory markers in pancreatic cells (PANC-1) induced by spike S1 protein (SARS-COV-2) DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0048] The present invention provides a recombinant Sclerotium rolfsii lectin for use in the treatment or prevention of an infectious disease caused by a Coronaviridae virus in a subject in need thereof.

[0049] The recombinant Sclerotium rolfsi lectin may comprise an amino acid sequence having at least 70% homology to SEQ ID NO: 1. In some embodiments, the amino acid sequence has at least 75%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO: 1.

[0050] In some embodiments, the recombinant Sclerotium rolfshii lectin comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4.

[0051] Methods for preparing recombinant proteins are well known to those skilled in the art. For example, a recombinant DNA molecule, such as a plasmid or viral vector, can be provided that contains a nucleic acid sequence encoding the lectin. The nucleic acid sequence can be operably linked to a promoter capable of controlling the expression of the lectin in a suitable host cell. The recombinant DNA molecule can be inserted into a suitable host cell, for example, by transformation, using methods known in the art. Suitable host cells include prokaryotic cells (e.g., E. coli) as well as lower eukaryotic cells (e.g., yeast cells) and higher eukaryotic cells. The host cells can then be cultured under suitable conditions, whereby the recombinant lectin is expressed. The recombinant lectin can then be obtained by isolation from the host cell as an expression product. The recombinant protein can be purified by conventional techniques known in the art, typically by conventional chromatographic methods.

[0052] In some embodiments, the recombinant Sclerotium rolfsii lectin protein is for use in the treatment or prevention of an infectious disease caused by a Coronaviridae family, the infectious disease caused by the Coronaviridae family being selected from, but not limited to, SARS-CoV2, SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, and variants thereof.

[0053] In some embodiments, the recombinant Sclerotium rolfsii lectin is for use in the treatment or prevention of an infectious disease caused by a Coronaviridae family, wherein the infectious disease caused by a Coronaviridae family is selected from SARS-CoV2 and variants thereof.

[0054] In some embodiments, recombinant S. rolfsii lectin can inhibit or reduce viral entry by blocking the spike S1 protein of SARS-CoV2 with ACE2. Recombinant S. rolfsii lectin interferes with SARS-CoV-2 entry into cells via AT1R downregulation and significantly inhibits related proteases in Covid pathogenesis.

[0055] In some embodiments, recombinant S. rolfsii lectin can inhibit or modulate the cytokine storm induced by mutant spike S1 protein (from SARS-CoV-2) in lung and immune cells. Recombinant S. rolfsii lectin of SEQ ID NO:2 significantly inhibits cytokines such as IL6 and IL8 in lung cells (A549) and immune cells (THP-1) compared to controls.

[0056] As known in the art, cytokines are small proteins involved in cell signaling. Cytokines include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors (TNFs). As used herein, "interleukins" (IL) include IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, IL-18, IL-1β, IL-17A, IL-17F, IL-22, IL-26, IL-23, IL-20, and IL-15.

[0057] In one embodiment of the present invention, recombinant S. rolfsii lectin of SEQ ID NO: 2 is capable of inhibiting proteases such as cathepsin L, 3CL, DPP4, etc., which are associated with COVID-19 disease. Recombinant S. rolfsii lectin of SEQ ID NO: 2 significantly inhibits proteases such as cathepsin L, 3CL, DPP4, etc., which play important roles in the biology of Covid 19 disease.

[0058] It will be understood that the term "treatment" includes the substantial cure (i.e., elimination) or reduction (permanent or temporary) of symptoms associated with infection with SARS-CoV2, or a variant thereof. Such symptoms can include cytokine storm.

[0059] It will be understood that the term "prevention" may include preventing the onset of infection with SARS-CoV2 or a variant thereof, or preventing or delaying the progression of disease caused by SARS-CoV2 or a variant thereof.

[0060] The treatment or prevention may comprise administering to the subject a therapeutically effective amount of recombinant S. rolfsii lectin. In some embodiments, the recombinant S. rolfsii lectin is administered at a dose of 0.001-1000 mg / kg, 0.5-100 mg / kg, or 1-50 mg / kg. It will be within the ability of one skilled in the art to determine the amount of lectin protein to be administered depending on the condition to be treated and the nature of the subject.

[0061] In some embodiments, the recombinant Sclerotium rolfsii lectin is administered in combination with an additional therapeutic agent.

[0062] In some embodiments, therefore, the present invention also provides a pharmaceutical composition comprising recombinant Sclerotium rolfsi lectin and a pharma- ceutically acceptable diluent or excipient, and optionally further comprising a therapeutic agent.

[0063] In some embodiments, the present invention further provides a method for treating or preventing a disease caused by SARS-CoV2 or a variant thereof in a subject, the method comprising administering recombinant Sclerotium rolfsii lectin or a pharmaceutical composition as described herein to the subject.

[0064] Administration of the recombinant Sclerotium rolfsi lectin or composition can be by any suitable route, including, but not limited to, injection (including intravenous (bolus or infusion), intraarterial, intraperitoneal, subcutaneous (bolus or infusion), intraventricular, intramuscular, or intrathecal), ingestion (e.g., tablet, gel, lozenge, or liquid), inhalation, topical, transmucosal (such as oral, nasal, or rectal mucosa), spray, tablet, transdermal patch, subcutaneous implant, or delivered in the form of a suppository.

[0065] In some embodiments, the recombinant S. rolfsi lectin (e.g., a recombinant lectin having the amino acid sequence of SEQ ID NO:2) or pharmaceutical composition described herein is administered enterally, parenterally, or topically to a subject. The lectin or pharmaceutical composition can be administered as a solid (e.g., tablet or capsule), lyophilized powder, liquid (e.g., solution or suspension), semi-solid, aerosol spray, or any other form of dosage form known to one of skill in the art. The lectin or pharmaceutical composition can be administered to a subject by depot injection, by injecting a solution or suspension intravenously, intramuscularly, intraperitoneally, subcutaneously, or intradermally, or can be administered intrathecally, transdermally, sublingually, or orally, topically, or by inhalation methods.

[0066] The subject may be a mammalian subject. In some embodiments, the subject is a human. In particular, the subject may be a human subject suffering from or seeking protection from SARS-CoV2 or a variant thereof.

[0067] The present invention relates to the treatment of a disease caused by SARS-CoV2 or a variant thereof using a recombinant S. rolfsii lectin having the amino acid sequence of SEQ ID NO: 2. The present invention also relates to a method for the prevention of a disease caused by SARS-CoV2 or a variant thereof, or the onset of a disease, or the progression of a disease in a subject, using a lectin such as SEQ ID NO: 2. The present invention further relates to a method for curing or reducing the effects of SARS-CoV2 in a subject using a recombinant S. rolfsii lectin such as SEQ ID NO: 2.

[0068] In one embodiment of the present invention, the effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 on inhibiting the binding of spike S1 protein to ACE2 was evaluated. SARS-CoV2 enters the human body via spike S1 protein, which binds to the ACE2 receptor present on the cells of lung cells. Inhibition of the binding of viral spike S1 protein to ACE2 protein is widely considered as a defense strategy against COVID-19. Various concentrations of recombinant S. rolfsii lectin of SEQ ID NO: 2 and positive control emodin were added and incubated with ACE2 inhibitor screening reagents in a 96-well plate (pre-coated with rabbit Fc-tagged SARS-Cov-2 spike SI RBD), and the absorbance was measured at a wavelength of 450 nm using a spectrophotometer. The results showed that recombinant lectin protein of SEQ ID NO:2 (0.01μg / ml-0.5μg / ml) showed 46.30%-62.70% inhibition of the binding of spike S1 protein to ACE2 protein, compared with the positive control emodin (0.1μg / ml-50μg / ml) which showed 38.9%-62.8% inhibition of the binding of spike S1 protein to ACE2 protein. From the above results, it is clear that recombinant S. rolfsii lectin of SEQ ID NO:2 can inhibit the binding of spike Sl to ACE2 protein and disrupt SARS-CoV-2 entry into cells via AT1R downregulation, thereby preventing the pathogenesis of SARS-CoV2.

[0069] In one embodiment of the present invention, the inhibitory effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 on mutant spike S1 protein (from SARS-COV-2) induced cytokine storm in lung and immune cells was evaluated. Human lung epithelial cells (A549) and immune cells (THP-1) were treated with recombinant S. rolfsii lectin of SEQ ID NO: 2 and mutant spike S1 protein (from SARS-COV-2) for 48 hours. Cytokine levels were determined in the supernatants and the inhibitory effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 on cytokine expression was measured by ELISA. The study revealed that significant inhibition of inflammatory cytokines induced by mutant SARS-COV-2 spike protein S1 in immune cells (percentage inhibition of IL6 ranges from 9% to 56% and IL8 ranges from 29% to 54%) and lung cells (percentage inhibition of IL6 ranges from 65% to 85% and IL8 ranges from 11% to 29%) indicates the anti-inflammatory potential of recombinant S. rolfsii lectin SEQ ID NO:2, thereby highlighting the role of recombinant S. rolfsii lectin SEQ ID NO:2 in suppressing cytokine storm and hyperinflammatory state in Covid-19.

[0070] In one embodiment of the present invention, the inhibitory effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 against proteases associated with COVID-19 disease was further evaluated using a cell-free assay. Proteases such as cathepsin L, 3CL, and DPP4 play important roles in COVID-19 infection. Cathepsins mediate the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein, thus facilitating coronavirus entry into human host cells, membrane fusion of the virus with host cell endosomes, and viral RNA release for subsequent replication. 3C-like protease (3CLpro) is essential for SARS-CoV replication. DPP4 interacts with the spike glycoprotein S1b domain to facilitate viral entry. Purified proteases were incubated with recombinant S. rolfsii lectin of SEQ ID NO: 2, and the corresponding fluorogenic substrates were used to evaluate the inhibitory effect. Recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 showed significant inhibition of cathepsin L (71.6%) and 3CL (26.2%), and moderate inhibition of DPP4 (16.7%). EXAMPLES

[0071] The following examples are presented to demonstrate the best mode of carrying out the invention, but are not intended to limit the invention in any manner.

[0072] Preparation of recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 Recombinant S. rolfsii lectin of SEQ ID NO:2 for injection was provided as a lyophilized cake in 2.5 mg quantities, dissolved in 1.2 mL water for injection to a final concentration of 2.5 mg / mL.

[0073] [Table 1]

[0074] Example 1 Effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 on inhibiting the binding of spike S1 protein to ACE2 protein The effect of recombinant S. rolfsii lectin of SEQ ID NO: 2 on the binding of spike S1 protein to ACE2 was evaluated using the SARS-CoV-2 spike-ACE2 interaction inhibitor screening assay kit. To a 96-well plate (pre-coated with rabbit Fc-tagged SARS-Cov-2 spike S1 RBD), 50 μL of immunoassay buffer (provided in the kit), 50 μL of recombinant S. rolfsii lectin of SEQ ID NO: 2 at various concentrations, positive control, and 50 μL of ACE2 inhibitor screening reagent were added and incubated for 30 min at RT. After incubation, 50 μL of spike inhibitor screening reagent was added to the wells and incubated for 30 min at RT. After incubation, the sample mixture was removed and the plate was washed 5 times with wash buffer (1×). 150 μL of anti-His-HRP conjugate (1×) was added to the wells and the plate was incubated for 30 min at RT on an orbital shaker. After incubation, the plate was washed 5 times with wash buffer (1x). 175 μL of TMB substrate was added to the plate and incubated for 20 minutes. The wells turned medium to dark blue in color. The reaction was stopped using stop buffer and the absorbance of each well was read at 450 nm using a synergy HT microplate reader. The % inhibition was calculated using the following formula: %Inhibition= (OD of control - OD of wells containing TI / PC) x 100 Control OD

[0075] [Table 2]

[0076] The results showed that recombinant Sclerotium rolfsii lectin with sequence ID No. 2 for injection showed 46.3%-62.7% inhibition of spike S1-ACE2 binding compared to the control.

[0077] Example 2 Determination of the non-cytotoxic dose of recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 A549 cells were seeded in DMEM + 10% FBS at a density of 10,000 cells / well of a 96-well culture plate and incubated at 37 °C for 24 h. THP-1 cells were seeded in RPMI + 10% FBS in a 96-well culture plate at a density of 10,000 cells / well and incubated at 37 °C for 24 h. Cells were serum starved for 24 h. The next day, cells were treated with various concentrations of recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 ranging from 10 ng / ml to 50 μg / ml. Untreated cells were used as controls. Cells treated with dexamethasone and hydroxychloroquine were included as positive controls. After treatment, cells were incubated at 37 °C for 24 h at 5% CO. 2 The cells were incubated for 48 hours in an incubator. The effect of recombinant S. rolfsii lectin of SEQ ID NO:2 on cell viability was estimated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

[0078] [Table 3]

[0079] [Table 4]

[0080] Recombinant S. rolfsii lectin of SEQ ID NO:2 at concentrations ranging from 10 ng / ml to 50 μg / ml showed greater than 70% cell viability in A549 and THP-1 cells compared to the control.

[0081] Example 2.1 Determination of cytokine levels by ELISA A549 and THP-1 cells were counted using a hemocytometer and seeded in tissue culture plates at a density of 0.1 x 106 cells / well of a 24-well plate in growth medium supplemented with 10% FBS. The above cells were incubated for 24 hours at 37°C in a 5% CO2 incubator. The cells were serum starved for 24 hours. The cells were treated with various concentrations ranging from 10ng / ml to 50μg / ml of recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 and stimulated with mutant spike S1 protein (from SARS-COV-2) for 48 hours. Cells treated with dexamethasone and hydroxychloroquine and stimulated with mutant spike S1 protein (from SARS-COV-2) were included as positive controls. Cells only stimulated with mutant spike S1 protein (from SARS-COV-2) were included as controls. Untreated cells were included as negative controls. After 48 hours, cell culture supernatants were collected from each well and stored at -20°C until analysis. The levels of inflammatory markers were determined by ELISA as follows: Assay diluent was added to each well. The respective kit standards and samples (cell supernatants) were pipetted directly into the wells and incubated for 2 hours at RT. After washing off unbound material a total of 5 times, the respective conjugate was added to each well and incubated for 1-2 hours at RT. After washing (5 times) to remove unbound conjugates, substrate solution was added to the wells and incubated for 30 minutes at RT in the dark. The reaction was stopped by adding stop solution to each well.

[0082] The optical density of the color was measured at 450 nm. The percent inhibition of each sample was determined as follows: [{Concentration of cytokines in control cells (stimulated with mutant spike protein only) (pg / ml)-Concentration of cytokines in test article + mutant spike protein treated cells (pg / ml)} / Concentration of cytokines in control cells (stimulated with mutant spike protein only) (pg / ml)]*100.

[0083] [Table 5]

[0084] Recombinant Sclerotium rolfsii lectin with sequence ID No. 2 for injection (10ng / ml to 50μg / ml) showed significant (p<0.001) inhibition of IL-8 and IL-6 compared to mutant SARS-COV-2-spike S1 protein (E484K) induced levels.

[0085] [Table 6]

[0086] Recombinant Sclerotium rolfsii lectin of sequence ID No. 2 (10ng / ml-50μg / ml) showed significant (p<0.001) inhibition of IL-8 and IL-6 compared to mutant SARS-COV-2-spike S1 protein (N501Y) induced levels.

[0087] Example 3 Evaluation of the inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 against COVID-19-associated proteases using cell-free assays The inhibitory effect of recombinant Sclerotium rolfsii lectin of SEQ ID NO: 2 against various proteases associated with COVID-19 was studied using specific cell-free enzyme-based assay kits.

[0088] Cathepsin L inhibitor screening assay Reagents were added in the same order as listed below:

[0089] [Table 7]

[0090] After addition of the substrate solution, the reaction mixture was incubated at room temperature for 60 min. Fluorescence was read in a microplate reader (excitation = 360 nm; emission = 460 nm). A decrease in fluorescence indicated inhibition of cathepsin L. Inhibition of cathepsin L: % Inhibition = [(RFU 酵素対照 -RFU TI / PC ) / RFU 酵素対照 ] * 100 It was calculated as follows.

[0091] [Table 8]

[0092] Conclusions Recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 (10μg / ml-250μg / ml) showed significant inhibition (p<0.001) of 31.4%-71.6% of cathepsin L compared to the enzyme control.

[0093] 3CL Protease, (SARSCoV-2) Assay Reagents were added in the same order as listed below:

[0094] [Table 9]

[0095] After addition of the substrate solution, the reaction mixture was incubated overnight at room temperature. Fluorescence was read in a microplate reader (excitation = 360 nm; emission = 460 nm). A decrease in fluorescence indicated inhibition of 3CL. Inhibition of 3CL: % Inhibition = [(RFU 酵素対照 -RFU TI / PC ) / RFU 酵素対照 ] * 100 It was calculated as follows.

[0096] [Table 10]

[0097] Conclusion: Recombinant Sclerotium rolfsii lectin of sequence ID No. 2 (10μg / ml-500μg / ml) showed significant inhibition (p<0.001) of 11.3%-26.2% of 3CL compared to the enzyme control.

[0098] DPP4 assay Reagents were added in the same order as listed below:

[0099] [Table 11]

[0100] After addition of the substrate solution, the reaction mixture was incubated at room temperature for 10 min. Fluorescence was read in a microplate reader (excitation = 360 nm; emission = 460 nm). A decrease in fluorescence indicated inhibition of DPP4. Inhibition of DPP4: % Inhibition = [(RFU 酵素対照 - RFU TI / PC ) / RFU 酵素対照 ] * 100 It was calculated as follows.

[0101] [Table 12]

[0102] Conclusion: Recombinant Sclerotium rolfsii lectin of sequence ID No. 2 (10μg / ml-125μg / ml) showed 4.6%-16.7% inhibition of DPP4 compared to the enzyme control.

[0103] Example 4 Inhibitory effect of recombinant Sclerotium rolfsii lectin of sequence number 2 on SARS-Cov-2 spike S1 protein-induced cytokine storm This study evaluated the inhibitory effect of recombinant S. rolfsii lectin, SEQ ID NO:2, on SARS-Cov-2 spike S1 protein-induced cytokine storm in bladder, heart, colon, vascular, kidney, bone, liver, and pancreatic cell lines. Cells were counted using a hemocytometer and seeded in growth medium supplemented with 10% FBS in 48-well tissue culture plates. Cells were incubated at 37°C in a 5% CO2 incubator for 24 hours, after which the cells were serum starved for 24 hours. Next, cells were treated with various concentrations of recombinant S. rolfsii lectin, SEQ ID NO:2, for injection for 24 hours and then stimulated with SARS-COV-2-spike S1 protein for 24 hours. Stimulation of cells with SARS-COV-2-spike S1 protein caused a significant increase in the levels of inflammatory cytokines compared to untreated levels. Cells treated with dexamethasone and hydroxychloroquine and stimulated with SARS-COV-2-spike S1 protein were included as a positive control. Cells only stimulated with SARS-COV-2-spike S1 protein were included as a control. Untreated cells were included as a negative control. After 24 hours, cell culture supernatants were collected from each well and stored at 20 degrees Celsius until analysis. The levels of inflammatory markers were determined by ELISA. The percent inhibition of each sample was determined as follows: [{Concentration of cytokine in control cells induced with spike protein only (pg / ml)-Concentration of cytokine in test article treated cells stimulated with spike protein (pg / ml)} / Concentration of cytokine in control cells induced with spike protein only (pg / ml)]*100.

[0104] [Table 13]

[0105] In bladder cells (T24), recombinant Sclerotium rolfsii lectin of sequence ID No. 2 (10ng / ml to 10μg / ml) showed significant (p<0.001) inhibition of pro-inflammatory cytokines IL-6 and IL-8 levels compared to the levels induced by spike S1 protein (SARS-COV-2).

[0106] [Table 14]

[0107] In cardiac cells (H9C2), recombinant Sclerotium rolfsii lectin with sequence ID No. 2 for injection (10ng / ml to 50μg / ml) showed significant (p<0.001) inhibition of proinflammatory cytokines, IL-6 and IL-8 levels compared to the levels induced by spike S1 protein (SARS-COV-2).

[0108] [Table 15]

[0109] In colon cells (HT-29), recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 (10ng / ml to 50μg / ml) showed significant (p<0.001) inhibition of proinflammatory cytokines, IL-6 and IL-8 levels compared to levels induced by spike S1 protein (SARS-COV-2).

[0110] [Table 16]

[0111] In vascular endothelial / vascular cells (EA.hy926), recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 (10ng / ml to 50μg / ml) showed significant (p<0.001) inhibition of pro-inflammatory cytokines, IL-6 and IL-8 levels compared to the levels induced by spike S1 protein (SARS-COV-2).

[0112] [Table 17]

[0113] In kidney cells (HEK-293), recombinant Sclerotium rolfsii lectin of sequence ID No. 2 (10ng / ml to 50μg / ml) showed significant (p<0.001) inhibition of pro-inflammatory cytokines, IL-6 and IL-8 levels compared to the levels induced by spike S1 protein (SARS-COV-2).

[0114] [Table 18]

[0115] In bone cells (MG-63), recombinant Sclerotium rolfsii lectin of SEQ ID NO:2 (10ng / ml to 50μg / ml) showed significant (p<0.001) inhibition of pro-inflammatory cytokines, IL-6 and IL-8 levels compared to levels induced by spike S1 protein (SARS-COV-2).

[0116] [Table 19]

[0117] In hepatocytes (HepG2), recombinant Sclerotium rolfsii lectin of sequence ID No. 2 (10ng / ml to 1μg / ml) showed significant (p<0.001) inhibition of the pro-inflammatory cytokine, IL-8 levels compared to the levels induced by spike S1 protein (SARS-COV-2).

[0118] [Table 20]

[0119] In pancreatic cells (PANC-1), recombinant Sclerotium rolfsii lectin of sequence ID No. 2 (10ng / ml to 50μg / ml) showed significant (p<0.001) inhibition of the pro-inflammatory cytokine, IL-8 levels compared to the levels induced by spike S1 protein (SARS-COV-2).

Claims

1. A recombinant Sclerotium rolfsii lectin protein of SEQ ID NO:1 or an amino acid sequence having at least 70% homology to SEQ ID NO:1 for use in the treatment or prevention of an infectious disease in a subject caused by the Coronaviridae family or a variant thereof.

2. 2. The recombinant Sclerotium rolfsii lectin protein of claim 1, wherein the amino acid sequence has at least 75%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:

1.

3. 2. The recombinant Sclerotium rolfsii lectin protein of claim 1, wherein the lectin protein is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:

4.

4. The recombinant Sclerotium rolfsii lectin protein of claim 1, wherein the recombinant lectin protein inhibits viral entry into cells by blocking the binding of SARS-CoV2 spike S1 protein to the ACE2 receptor.

5. The recombinant Sclerotium rolfsii lectin protein of claim 1, wherein the recombinant lectin protein regulates the cytokine storm induced by the spike S1 protein of coronavirus family or its mutants by inhibiting cytokines such as IL6 and IL8.

6. The recombinant lectin protein is a) AT1R downregulation, or b) inhibition of proteases such as cathepsin L, 3CL, and DPP4; The recombinant Sclerotium rolfsii lectin protein of claim 1, which interferes with SARS-CoV2 entry into cells by

7. 2. Use of a recombinant Sclerotium rolfsii lectin protein according to claim 1 for the manufacture of a medicament for use in the treatment or prevention of an infectious disease caused by the Coronaviridae family or its variants.

8. A pharmaceutical composition comprising a recombinant Sclerotium rolfsii lectin protein of SEQ ID NO:1 or an amino acid sequence having at least 70% homology to SEQ ID NO:1 and a pharma- ceutically acceptable diluent or excipient for use in the treatment or prevention of an infectious disease caused by a coronavirus or a variant thereof.

9. 9. The pharmaceutical composition of claim 8, wherein the infectious disease caused by a coronavirus or a variant thereof is a disease caused by SARS-CoV2, SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, and variants thereof.

10. 10. Use of the composition of claim 8 for the manufacture of a medicament for use in the treatment or prevention of an infectious disease caused by a coronavirus or a variant thereof.

11. A method for treating or preventing an infectious disease caused by a coronavirus or a variant thereof in a subject, comprising administering to the subject a therapeutically effective amount of a recombinant Sclerotium rolfsii lectin protein having an amino acid sequence of SEQ ID NO:1 or an amino acid sequence having at least 70% homology to SEQ ID NO:

1.

12. 12. The method of claim 11, wherein the infectious disease caused by a Coronaviridae or a variant thereof is a disease caused by one or more viruses selected from SARS-CoV2, SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, and variants thereof.

13. The method of claim 11, wherein the recombinant lectin protein inhibits the interaction or binding of SARS-CoV2 spike S1 protein with the ACE2 receptor and inhibits or modulates the cytokine storm induced by the spike S1 protein of a coronavirus or its mutants.

14. The method of claim 11, wherein the treating or preventing comprises administering the lectin protein at a dose of 1 to 50 mg / kg.

Citation Information

Patent Citations

  • Plant lectin succ-Con A for treating corona virus infection and application

    CN113262294A

  • Application of Lens culinaris agglutinin in preparation of medicine for preventing and treating infectious diseases caused by coronavirus

    CN113274484A

  • Cancer cell binding recombinant lectins with antitumor activity and method of preparation

    WO2010095143A2

  • Recombinant lectin and method of preparing thereof

    WO2014203261A2

  • Protein for treatment of inflammatory diseases

    WO2020074984A1